Benefit of interferon β-1a on MSFC progression in secondary progressive MS

Cohen, Jeffrey A.; Cutter, Gary; Fischer, Jill S.; Goodman, Andrew; Heidenreich, Fedor; Kooijmans, Mariska; Sandrock, AW; Rudick, Richard A.; Simon, Jack H.; Simonian, Nancy A.; Tsao, Elisa; Whitaker, J. N.

doi:10.1212/wnl.59.5.679

Cited by 379 publications

(256 citation statements)

References 34 publications

Supporting

Mentioning

243

Contrasting

Unclassified

Order By: Relevance

“…The International MS Secondary Progressive Avonex Controlled Trial (IMPACT) studied the effect of IFNB-1a IM 60 μg (double the current RRMS treatment dose) vs placebo in a total of 436 participants over 2 years [38]. A unique aspect of this SPMS trial was the use of the MS Functional Composite (MSFC) as the primary outcome, a composite of the timed 25-foot walk (lower extremity function), the 9-hole peg test (upper extremity function), and the paced auditory serial addition test (PASAT3, cognitive function).…”

Section: Progressive Formsmentioning

confidence: 99%

Interferon Beta and Glatiramer Acetate Therapy

McGraw

Lublin

2013

Neurotherapeutics

View full text Add to dashboard Cite

Section: Progressive Formsmentioning

confidence: 99%

Interferon Beta and Glatiramer Acetate Therapy

McGraw

Lublin

2013

Neurotherapeutics

View full text Add to dashboard Cite

“…42 The primary outcome measure was change in the MS Functional Composite score (MSFC), an outcome measure that combines three domains: upper arm and hand function, cognition, and ambulation; it is expressed as a composite Z-score. 43 Two-year worsening in MSFC was reduced by 40.4% (P ϭ 0.033) in the treatment arm; this was attributable largely to preservation of upper extremity function as measured by the nine-hole peg test.…”

Section: Secondary Progressive Msmentioning

confidence: 99%

Interferon-β Treatment for Multiple Sclerosis

Bermel

Rudick

2007

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-␤, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in early, active patient populations have established the clinical efficacy of interferon-␤ in reducing relapses and delaying disability progression. Although its mechanism of action remains incompletely understood, a reduction in active lesions seen on magnetic resonance imaging implies primary anti-inflammatory properties, a mechanism supported by basic immunologic research. Variation in individual patient responsiveness to interferon-␤ may be due to disease variability or differential induction of interferon-stimulated genes. The magnitude of the therapeutic effect appears to be similar among products, but the optimal dose, route, and frequency of administration of the drug remain uncertain.

show abstract

“…31 The median MSFC z-score change was reduced by 40.4% in IFNβ-1b patients compared with placebo, whereas there was no benefit demonstrated by the EDSS. 31 These findings suggest that the MSFC is more sensitive to change in disability than is the EDSS.…”

mentioning

confidence: 91%

Measuring Disability Progression with the Multiple Sclerosis Functional Composite

Krysko¹,

O’Connor²

2010

US Neurology

View full text Add to dashboard Cite

The multiple sclerosis functional composite (MSFC) is a three-part quantitative objective measure of neurologic function, measuring leg (timed 25-foot walk [25FTW]), arm (nine-hole peg test [9HPT]), and cognitive (three-second paced auditory serial addition test [PASAT3]) function. The MSFC was developed to be a more sensitive measure of disability than the expanded disability status scale (EDSS) and has excellent reliability. Validity is supported by moderately strong correlations with EDSS, brain atrophy, and quality of life. Advantages of the MSFC include its continuous scale and inclusion of several disease dimensions. Limitations include practice effects, the lack of a visual function component, variations in reference populations, and limited understanding of clinically relevant MSFCz-score changes. MSFCz-score change has been used as a secondary end-point in MS trials, but EDSS progression remains the primary disability outcome. A new approach to MSFC data involves defining MSFC progression as worsening in an MSFC component by 15–20% over three months. With further study, this could be used as a primary disability outcome in future clinical trials.

show abstract

Benefit of interferon β-1a on MSFC progression in secondary progressive MS

Abstract: IFNbeta-1a demonstrated benefit on MSFC progression, relapses, quality of life, and MRI activity in SPMS.

Cited by 379 publications

References 34 publications

Interferon Beta and Glatiramer Acetate Therapy

Interferon Beta and Glatiramer Acetate Therapy

Interferon-β Treatment for Multiple Sclerosis

Measuring Disability Progression with the Multiple Sclerosis Functional Composite

Contact Info

Product

Resources

About